期刊文献+

贝那普利治疗慢性充血性心力衰竭患者最佳剂量 被引量:26

The best dose of benazepril in treatment of chronic congestive heart failure
下载PDF
导出
摘要 目的观察不同剂量贝那普利治疗慢性充血性心力衰竭(CHF)的疗效。方法入选2013年3月至2015年5月在河北医科大学哈励逊国际和平医院门诊就医的轻中度CHF患者240例,其中男126例,女114例,年龄60-81岁,平均(73.40±6.35)岁,病程3-15年。按照随机对照的原则分为A组(76例)、B组(86例)、C组(78例)三个治疗组。三组间基础疾病、诱因、年龄、性别及心功能状况等临床资料比较,差异无统计学意义(P均〉0.05),具有可比性。三组患者均进行基础治疗。同时A组给予贝那普利5 mg,1/日;B组给予贝那普利10 mg,1/日,观察3周后若收缩压〉90 mm Hg(1mm Hg=0.133k Pa),未发生低血压,血肌酐升高不超过50%基线水平,则继续治疗;如果患者不耐受,贝那普利可恢复至5 mg治疗;C组给予贝那普利20 mg,1/日,同时观察患者耐受情况。连续治疗12个月后进行疗效评估和记录不良反应。治疗前后测定左室射血分数(LVEF)、左室舒张末期内径(LVEDD)及左室收缩末期内径(LVESD),6 min步行试验距离和脑钠肽(BNP)水平。结果 A组患者总有效率为80.2%,B组为87.2%,C组为96.1%。总有效率C组较A组和B组升高,差异有统计学意义(P均〈0.05)。与治疗前比较,三组患者治疗后LVEDD、LVESD、LVEF均改善,差异有统计学意义(P均〈0.05)。与A组和B组比较,C组LVEDD、LVESD、LVEF指标改善更明显,差异有统计学意义(P均〈0.05)。与治疗前比较,三组治疗后BNP水平下降,6 min步行距离增加,差异有统计学意义(P均〈0.05)。与A组和B组治疗后比较,C组BNP水平下降,6 min步行距离增加,差异有统计学意义(P均〈0.05)。结论贝那普利20 mg较5 mg和10 mg治疗慢性充血性心力衰竭更有效,更有效地改善心功能,安全性较好。 Objective To observe the curative effect of benazepril in different doses in treatment of chronic congestive heart failure (CHF). Methods CHF patients with disease course from 3 y to 15 y (n=240, male 126, female 114, aged from 60 to 81 and average age=73.40 + 6.35) were chosen from Mar. 2013 to May 2015. The patients were randomly divided into group A (n=76), group B (n=86) and group C (n=78), and the comparison in basic diseases, cause, age, sex and heart function had no statistical difference among 3 groups (all P〉0.05). Besides of basic therapy, group A were given benazepril (5 mg, qd), group B, (10 rag, qd) and group C (20 mg, qd). After treatment for 12 m, the curative effect was reviewed and adverse reactions were recorded. The levels of left ventricular ejection fraction (LVEF), left ventricular end-diastolic inner diameter (LVEDd), left ventricular end-systolic diameter (LVESd), 6-minute walk test (6MWT) and brain natriuretic peptide (BNP) were detected before and after treatment. Results The total effective rate was 80.2% in group A, 87.2% in group B and 96.1% in group C, which was higher in group C than that in group A and group B (all P〈O.05). LVEDd, LVESd and LVEF were improved in 3 groups after treatment (all P〈0.05). Compared with group A and group B, the improvements of LVEDd, LVESd and LVEF were more significant in group C (all P〈O.05). The level of BNP decreased and 6MWT increased in 3 groups after treatment (all P〈0.05). The level of BNP decreased and 6MWT increased in group C compared with group A and group B after treatment (all P〈0.05). Conclusion Benazepril in dose of 20 mg has higher curative effect than that in dose of 5 mg and that in 10 mg on CHF, and can improve more effectively heart function with higher safety.
出处 《中国循证心血管医学杂志》 2016年第1期40-42,共3页 Chinese Journal of Evidence-Based Cardiovascular Medicine
基金 2013年衡水市科研基金资助项目(13005z)
关键词 贝那普利 剂量 充血性心力衰竭 临床疗效 心功能 benazepril dose congestive heart failure(CHF) clinical efficacy heart function
  • 相关文献

参考文献6

二级参考文献66

  • 1王屹,潘梓青,丁林峰.快速脑钠素测定在慢性心力衰竭诊断中的应用[J].实用老年医学,2004,18(5):272-273. 被引量:7
  • 2黄琼,徐伟建.参附注射液对压力后负荷性急性心衰大鼠血流动力学的影响[J].实用中西医结合临床,2005,5(2):6-7. 被引量:21
  • 3曹伟.趋美欣治疗充血性心力衰竭35例疗效观察[J].航空航天医药,2011,22(1):90-91. 被引量:1
  • 4王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量:90
  • 5心肌病诊断与治疗建议[J].中华心血管病杂志,2007,35(1):5-16. 被引量:552
  • 6Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80(11A) : 15L-25L
  • 7Braunwald E,Bristow MR Congestive heart failure: fifty years of progress. Circulation, 2000, 102(20 Suppl 4) : Ⅳ14-23.
  • 8Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112 (12) :e154-235.
  • 9Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary ( update 2005 ):The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26(11): 1115-1140.
  • 10Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006 : diagnosis and management. Can J Cardiol, 2006, 22 (1): 23-45.

共引文献3731

同被引文献218

引证文献26

二级引证文献163

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部